SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
About SpringWorks Therapeutics, Inc.
- NASDAQ: $SWTX
- Notified: $46.55
- 06:30 EDT
